Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. has demonstrated an encouraging upward trend in revenue, achieving $422,000 in Q2, marking a significant increase from $197,000 in Q1. The company's projections indicate robust revenue growth, forecasting an increase to $1.3 million in 2025 and further to $4.5 million in 2026. This anticipated growth is underpinned by RenovoRx's innovative Trans-Arterial Micro-Perfusion therapy platform, aimed at addressing high unmet medical needs in cancer treatment, which positions the company well within the biopharmaceutical sector.

Bears say

RenovoRx Inc is facing significant challenges due to the high unmet medical need in the pancreatic cancer treatment market, where the 5-year survival rate is only 12%, highlighting the severe limitations in therapeutic options. The company reported a modest revenue of $0.4 million paired with a net loss of $2.9 million, indicating ongoing financial struggles that align closely with consensus estimates, thus offering little positive deviation to suggest financial improvement. Furthermore, while the company has potential in its proprietary therapy platform, the overwhelming concerns regarding its current performance and the market's harsh realities contribute to a negative outlook on its stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.